biostudies-literatureBarclay MEDepartment of Health, Government of Western AustraliaCancer Council VictoriaCancer Research UKKreftforeningenPublic Health WalesAHRQ HHSKræftens BekæmpelseDG Health and Social Care of the Scottish GovernmentCancer Society of New ZealandPartenariat Canadien Contre Le CancerNational Cancer Registry IrelandPublic Health Agency Northern IrelandCancer Institute NSWNational Health Service Englande000800https://www.ebi.ac.uk/biostudies/studies/S-EPMC12258358biostudies-literatureUnknown4(1)<h4>Abstract</h4><h4>Background</h4>International variation in lung cancer survival may be partly explained by variation in stage-specific treatment use, but relevant comparative evidence is sparse. As part of the International Cancer Benchmarking Partnership, we examined use of chemotherapy and radiotherapy in population-based cancer registry data.<h4>Methods</h4>Linked population-based data sources were used to describe use and time to first treatment for either chemotherapy or radiotherapy in patients with lung cancer diagnosed in study periods during 2012-2017 in 16 jurisdictions of Australia, Canada, the UK and Norway.<h4>Results</h4>There was large variation in the proportions of patients with lung cancer receiving chemotherapy (ranging from 23% in Northern Ireland to 45% in Norway) BMJ oncologyChemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012-2017: an ICBP population-based study.PMC12258358R01 HS024284C18081/A18180International Cancer Benchmarking PartnershipEDDAPA-2022/100002Saint-Jacques NShack LFinley CJLawler MHabbous SRansom DTDewar RAWang HFung SSwann RDawkins PANavas EGButler JDenny CAZhang BSarker SMorrison DSGreen KEWoods RRNilssen YMoller BBucher OThomson CSMcClure CAICBP Module 9 Lung Study GroupBaldwin DBarisic ACreighton NWong THTDonnelly DWFinn NHarrison SMay LJohnson SABarclay MEKumar SEHuws DWAlvi RDowden JJWalton RCameron DABennett DBTe Marvelde LMcPhail STian XDownie LThomas RJHan JMusto GYou HLyratzopoulos GfalseChemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012-2017: an ICBP population-based study.<h4>Abstract</h4><h4>Background</h4>International variation in lung cancer survival may be partly explained by variation in stage-specific treatment use, but relevant comparative evidence is sparse. As part of the International Cancer Benchmarking Partnership, we examined use of chemotherapy and radiotherapy in population-based cancer registry data.<h4>Methods</h4>Linked population-based data sources were used to describe use and time to first treatment for either chemotherapy or radiotherapy in patients with lung cancer diagnosed in study periods during 2012-2017 in 16 jurisdictions of Australia, Canada, the UK and Norway.<h4>Results</h4>There was large variation in the proportions of patients with lung cancer receiving chemotherapy (ranging from 23% in Northern Ireland to 45% in Norway) 2025-01-01T00:00:00Z20252026-06-02T00:16:26.472Z2026-05-24T03:07:37.289ZS-EPMC122583584066215810.1136/bmjonc-2025-000800